Arovella Therapeutics Limited, a biotechnology company, engages in the development of therapies for the treatment of cancer in Australia and internationally. It product pipeline includes ALA-101 CD19, which is a next-generation off-the-shelf CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukaemias; ALA-105 CLDN18.2 for targeting Claudin 18.2, which is expressed in gastric cancer, gastroesophageal junction cancer, pancreatic cancer, and lung and ovarian cancer; and IL-12-TM for treating solid tumors. The company was formerly known as Suda Pharmaceuticals Ltd and changed its name to Arovella Therapeutics Limited in October 2021. Arovella Therapeutics Limited was incorporated in 1999 and is based in Preston, Australia.
Price analytics
Returns
1 day
0.0%
1 week
-13.0%
1 month
-21.7%
3 months
-29.9%
6 months
-32.9%
1 year
-51.0%
3 years
-39.7%
Risk
Volatility (1y ann.)
58.2%
Beta vs ASX 200
0.57
Sharpe (1y)
-1.02
VaR 95% (1-day)
-4.8%
Max drawdown (1y)
-53.0%
Off 1-year high
-53.0%
Technicals
RSI(14)
12
OS
vs 50DMA
-20.7%
vs 200DMA
-35.3%
Trend
Death cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value73.1
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
57
Price / Sales
0
Growth50.0
Revenue growth (1y)
100
Revenue CAGR (3y)
0
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income—
No meaningful dividend — pillar excluded from the overall score.
Momentum0.3
6-month return vs ASX 200
0
Price vs 200-day average
0
Price vs 50-day average
0
Position in 52-week range
1
Hover a row's info icon for the exact rule. Bounds and weights are configurable in
the Django admin (Scoring configuration).